StockWatch
·

Harsha Engineers International Ltd Q1 FY27 Results

HARSHAQ1 FY27 Results
Filing
Result:Weak· Market: CrashedMargin squeezeCost led

Beat/Miss: Miss · Outlook: Cautiously Optimistic · Guidance: Raised

MetricValueQ4 FY26Q1 FY26
Revenue457.43 Cr3.5%25.2%
Total Income462.56 Cr4.5%23.0%
Expenditure409.59 Cr2.3%26.8%
PBT52.97 Cr19.0%0.2%
Net Profit37.38 Cr20.9%1.4%
OPM14.75%0.74pp0.42pp
NPM8.08%1.67pp2.01pp
EPS4.1120.8%1.4%
View full financials

Revenue grew a strong 25.2% YoY but adjusted PAT was flat-to-down (-1.4% YoY, -20.9% QoQ) as core segment margins compressed to ~11.9% from ~15%, missing both management's guidance and street's margin expectations despite the revenue beat.

HARSHA ENGINEERS · Q1 FY27 · THE VERDICT

₹457 Crore Revenue, ₹37 Crore Profit — The Margin Recovery Thesis Starts Here

Harsha delivered 25% revenue growth but flat profit, pivoting management guidance lower on raw material pass-through lag. The call reveals why the street sold off day-1, and what it will take to believe the margin rebound.

17 Aug 2026 · 6 min read
Reported Revenue

₹457.4 Cr

+25.2% YoY

Reported PAT

₹37.4 Cr

-1.5% YoY

EBITDA Margin

15.9%

−150 bps YoY

India Segment Growth

21% YoY

6% QoQ

The gap between this quarter's topline and bottom line is the entire story. Harsha's revenue engine is firing—25% consolidated growth, 21% in the core India engineering segment, and 35% in bushing. But net profit barely moved. On the call, management downgraded the year-ahead margin band from 24% (Q1 standalone) to 20–22%, citing 8% raw material cost inflation and a 1–2 quarter lag before customer price acceptance kicks in. The street's -2.08% day-1 sell-off was not overreaction; it was the market repricing the company from a "growth inflects profit" narrative to a "grow into margin compression" one.

Where the profit compression came from

EBITDA fell 150 basis points year-over-year—to 15.9% from 17.4%—despite 25% revenue growth. Two factors explain it. First, raw material prices (brass, copper, zinc, steel, polymer) rose 8% globally; the company operates on indexed pricing with a 1–2 quarter lag, so Q1 bore the cost inflation before customer passes-through became visible. Second, a ₹4 crore FX hedge loss on Romania operations masked an otherwise stronger operating result. Together, these created the arithmetic: revenue up 25%, EBITDA margin down 150 bps, and profit down 1.5%. Management is confident the RM pass-through will normalize margins by H2 FY27, but that depends on customer acceptance and competitive dynamics—neither guaranteed.

Management claims vs. what holds up

Satisfactory Q1 performance in line with management plan

Overstated

Revenue +25% YoY beat guidance; PAT −1.5% despite topline growth missed margin expectations

Pass-through of 8% RM increase will normalize margins in Q2

Partial

OPM fell 150 bps YoY; pass-through timing unverified, depends on customer acceptance and competitive dynamics

Strong 21% growth in India Engineering with 6% QoQ growth

Supported

Confirmed; India segment delivered exactly 21% YoY and 6% QoQ despite macro headwinds

Bushing targeting 30% growth FY27 with strong visibility

Supported

Q1 delivered 35% YoY; order book and pipeline assurances backed by new product pipeline (wind, EV)

Advantek ₹140 Cr+ revenue target for FY27

Contradicted

Q1 ₹30 Cr, FY26 ₹43 Cr; requires ₹35 Cr/qtr run-rate from current ₹30 Cr over 9 months—3.25x growth highly aggressive

What changed on this call

  • India growth guidance upgraded: mid-teens → high-teens (16%+ support)

  • Japan customer downgraded: 25% Q1 growth but guiding only 10% FY27 (₹80 Cr); slow project pipeline

  • Margin band narrowed: 24% Q1 standalone → 20–22% FY27 guidance (RM costs + capex ramp)

  • Romania losses timeline pushed: 'gradual reduction' to ₹2–3 Cr by FY27 end; breakeven now 'maybe next year'

The market's take

On day 1, the stock fell 2.08% with heavy delivery (84.5%), signaling institutional selling. By day 3, it recovered only +0.44%—a clear verdict that the market doesn't believe the RM pass-through thesis yet. At ₹412.25, the stock is 12.1% below its all-time high of ₹469, trading below its 50-day moving average (₹416.39) but above its 200-day (₹389.38). Volume has increased, but momentum remains neutral (RSI 53.3). FII ownership trimmed 0.58 percentage points in Q1 (now 1.79%), while domestic institutions added 0.59 percentage points (now 13.02%), suggesting foreign investors are skeptical of the margin recovery narrative while DIIs are buying the capex thesis. The street is right to wait: until Q2 shows RM pass-through visibly restoring EBITDA margin toward 18%+, the stock deserves to trade in the ₹390–₹420 range, not back toward the highs.

The bull-bear ledger

  • 25% consolidated revenue growth; 21% India segment growth despite macro headwinds

  • Bushing +35% YoY; Stamping +31% YoY; new product pipeline (wind gearbox, rails, aerospace, EV) credible

  • India export ₹139 Cr (+22% YoY); broad-based global demand across Europe, US, bearing OEMs

  • CapEx execution on track: Bhayla Phase-2 construction rolling; China brownfield Q3 FY28 commissioning

  • PAT flat (−1.5%) despite 25% topline growth; margin compression unresolved, not a temporary cost spike

  • Margin guidance walked down: 24% → 20–22%; recovery depends on customer acceptance of price hikes (unproven)

  • Advantek needs 3.25x growth in 9 months to hit ₹140 Cr; PAT positive by FY27-end unverified

  • Romania continues loss-making despite topline growth; breakeven timeline pushed to 'maybe FY28'; combined China + Romania loss ₹6 Cr still

  • Japan customer guidance downgraded to 10% FY27 despite 25% Q1 growth; project pipeline described as 'very slow'

  • Large-size Cages only ₹10 Cr in Q1 vs 50% FY27 growth target; new facility ramping slower than expected

Risks, ranked by how much they should concern a holder

RM cost pass-through acceptance & timing

High

8% material cost increase is pending 1–2 quarter lag. If customers resist price hikes or competitive dynamics prevent full pass-through, margin recovery extends beyond H2 FY27. OPM down 150 bps YoY is structural, not cyclical.

Advantek ramp-up execution

High

₹140 Cr FY27 target requires ₹35 Cr/qtr run-rate starting Q2; Q1 was only ₹30 Cr. PAT positive by FY27-end is unproven. Any stumble in new customer wins or product adoption derails the target and compounds margin dilution.

Romania profitability path unclear

High

Combined China + Romania loss ₹6 Cr in FY26; guiding ₹2–3 Cr by FY27-end. Q1 saw ₹2 Cr FX loss on Romania, masking operational issues. Management hedged with 'gradually reduce losses' and 'maybe next year' breakeven—precision is absent.

Large-size Cages ramp slowness

Medium

Q1 only ₹10 Cr vs 50% FY27 growth target (implying ₹50 Cr+ revenue). New facility underutilized; if ramp delays persist, the high-value segment becomes a drag on consolidated margin recovery.

Japan customer deceleration

Medium

Q1 ₹21 Cr (+25% YoY) but FY27 guidance only 10% (₹80 Cr). Slow project pipeline acknowledged. If new projects don't materialize, the segment underperforms and reduces consolidated revenue visibility.

The debate

What to watch next

  • 1 · Q2 FY27 EBITDA margin recovery (October 2026)

    This is the linchpin. If India segment EBITDA margin rebounds to 22%+ in Q2, the RM pass-through narrative holds and margin recovery is underway. If it stays 19–20%, customers are resisting price hikes and the bear case (margin compression structural) has teeth. Watch consolidated EBITDA margin; if it's 17%+, the pass-through is working.

  • 2 · Advantek sequential ramp (Q2 & Q3 FY27)

    Q1 was ₹30 Cr; Q2 needs to be ₹32+ Cr and Q3 ₹35+ Cr to reach the ₹140 Cr FY27 target. If Advantek stalls at ₹30–31 Cr/qtr, the 3.25x growth target is at risk, and PAT positive by FY27-end becomes unlikely. EBITDA margin at Advantek (management guided 9% in Q1) is also critical; if it stays 8–10%, the subsidiary remains a dilutant.

  • 3 · Romania + China loss trajectory (H2 FY27)

    Management guided ₹2–3 Cr combined loss by FY27-end (vs ₹6 Cr in Q1). If H2 shows losses narrowing materially, the turnaround narrative gains credibility. If combined losses stay ₹5+ Cr, the subsidiary drag persists and the bull case weakens.

This is steady execution, not a step-change. Harsha is growing revenue and scaling capex on time, but margin recovery is uncertain and execution risk is real. The stock deserves to trade below the ₹430–₹469 range (near-term highs) until Q2 proves the RM pass-through is working. The single number to track from here is India segment EBITDA margin in Q2; if it's 22%+, the bull case re-rates and the stock moves back toward ₹420+. If it's 20% or lower, the market's skepticism is justified and the stock stays range-bound. Hold for the capex upside (FY28–29), but don't chase the near-term margin recovery story until it's visible.

Informational and educational content only. Not investment advice.

Harsha Engineers International Ltd (HARSHA) Q1 FY27 Results, Transcript & Analysis — StockWatch